# Measles-rubella microarray patch (MR–MAP) target product profile

JUNE 2019





# Measles-rubella microarray patch (MR–MAP) target product profile

JUNE 2019





Measles-rubella microarray patch (MR-MAP) target product profile

ISBN 978-92-4-000020-9 (WHO)

#### © World Health Organization and the United Nations Children's Fund (UNICEF), 2020

This joint report reflects the activities of the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF).

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO or UNICEF endorses any specific organization, products or services. The unauthorized use of the WHO or UNICEF names or logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO) or the United Nations Children's Fund (UNICEF). Neither WHO nor UNICEF are responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules).

Suggested citation. Measles-rubella microarray patch (MR–MAP) target product profile. Geneva: World Health Organization and the United Nations Children's Fund (UNICEF), 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

**Sales, rights and licensing.** To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO or UNICEF concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO or UNICEF in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO and UNICEF to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO or UNICEF be liable for damages arising from its use.

Design and layout by Lushomo www.lushomo.net

# **Contents**

ContentsiPrefaceiAcknowledgementsvAbbreviationsv						
				1.	Introduction	1
				2.	General considerations for an mr vaccine delivered by MAPs Indication Use-case scenarios Dose regimen and schedule Formulation Presentation	<b>2</b> 2 3 3 3
				3.	Generic product characteristics for an MR vaccine on solid coated or in dissolvable MAPs Target population Target countries Safety Immunogenicity Stability Vaccine vial monitors (VVM) Dosage	<b>4</b> 4 5 5 6 6 7
4.	Generic product characteristics for MAPs for delivery of MR vaccinesProduct registration pathDose presentationPrimary and secondary packagingTertiary packagingLabellingRoute of administrationHuman factors (HF)ApplicationUser training requirementsDelivery time: time required to apply the mapWear time: minimal time that the map must be worn for the entire dose of the vaccine to be successfully deliveredDelivery: indication of a successful vaccinationDelivery: application siteReactogenicityCost per immunized childDisposal	<ul> <li>8</li> <li>8</li> <li>9</li> <li>9</li> <li>9</li> <li>10</li> <li>10</li> <li>10</li> <li>10</li> <li>10</li> <li>11</li> <li>11</li> <li>11</li> <li>12</li> <li>12</li> <li>12</li> <li>12</li> <li>13</li> <li>13</li> </ul>				

## **Preface**

This target product profile (TPP) describes the minimal and optimal product characteristics for a measles and rubella (MR) microarray patch (MAP) vaccine, with a particular focus on delivery considerations for low- and middle-income countries (LMICs). It is intended to inform MAP developers, vaccine developers, procurement agencies and funders on MR–MAP research and public health priorities, and to facilitate the most expeditious development of MR–MAP candidates that would address the greatest and most urgent public health need in LMICs.

The document is based on an initial MR–MAP TPP developed by PATH and the World Health Organization (WHO) in 2016. It has been updated following input from a WHO working group of independent subject matter experts from diverse areas of expertise, including epidemiology, immunology, manufacturing and clinical development, regulatory affairs, health economics and policy. Specific aspects of the TPP were refined through consultations with various immunization stakeholders including the Immunization Practices Advisory Committee (IPAC) and the TechNet-21 community.

A draft was disseminated widely for public consultation in December 2018 among relevant stakeholders including MAP developers and vaccine manufacturers. The comments received were reviewed by the WHO MR–MAP working group and, where appropriate, incorporated into the TPP. This updated version is endorsed by the United Nations Children's Fund (UNICEF) and co-published with WHO.

While this document contains assumptions concerning regulatory considerations to help frame the rationale for the proposed characteristics, this TPP should not be considered as a regulatory document. The TPP will be updated as product development of MAP technology evolves, or as other changes in the identified need or research and development landscape emerge.

The document is divided into three major sections:

- General considerations comparing the attributes of an MR vaccine delivered by MAP with those of the current, lyophilized MR vaccine;
- 2. Generic product characteristics for an MR vaccine on solid coated or dissolvable MAPs; and
- 3. Generic product characteristics for MAPs for delivery of MR vaccines.

Sections 2 and 3 describe the minimally acceptable and optimal targets for MR–MAP product attributes. However, these attributes are not currently listed in order of priority or importance; should an MR–MAP profile be sufficiently superior to the minimal characteristics under one or more categories, this may outweigh deficiencies in meeting a specific minimal characteristic in the suitability of product procurement.

The primary target audience for this TPP is any entity intending to develop a vaccine for national immunization programme use, including in low resource settings, and eventually to seek WHO prequalification and UNICEF procurement following licensure of its product. However, it is important to note that while this TPP defines aspirational goals for MR–MAP vaccine attributes, it does not supersede the evidence-based assessment by WHO's Strategic Advisory Group of Experts on Immunization (SAGE) for policy recommendation on use; other existing WHO guidance on vaccine development or prequalification; or assessments conducted by national regulatory authorities (NRAs), the European Medicines Agency (EMA), or the United States Food & Drug Administration (FDA).

## **Acknowledgements**

he Department of Immunization, Vaccines and Biologicals at WHO, and UNICEF would like to thank the many individuals who contributed to the development of this document. Particular appreciation is extended to the members of the WHO MR-MAP working group for their assistance with drafting and review: Jean-Pierre Amorij, UNICEF focal point, Copenhagen, Denmark; Robin Biellik, Consultant, Lausanne, Switzerland, chair of the Programmatic Suitability for Prequalification (PSPQ) Steering Committee; Shanda Boyle, Consultant, Seattle WA, United States of America (USA); David Durrheim, University of Newcastle, Newcastle, Australia; Michael J. Free, Consultant and member of IPAC, Seattle WA, USA; Birgitte Giersing, WHO focal point, MR-MAP working group coordinator, secretariat of the WHO Product Development for Vaccines Advisory Committee (PDVAC), Geneva, Switzerland; Mateusz Hasso-Agopsowicz, WHO, Geneva, Switzerland; Katrina Kretsinger, WHO, Geneva, Switzerland; Martin I. Meltzer, United States Centers for Disease Control and Prevention (CDC), Atlanta GA, USA; William Moss,

Johns Hopkins University, Baltimore MD, USA; Mark Papania, CDC, Atlanta GA, USA (PDVAC member); Nicolas Peyraud, Médecins sans Frontières, Geneva, Switzerland; Pieter Neels, Consultant, Antwerp, Belgium; David Robinson, Bill & Melinda Gates Foundation, Seattle WA, USA; James M. Robinson, Consultant, St Augustine FL, USA; Marian Wentworth, Management Sciences for Health, Arlington VA, USA (PDVAC member); Darin Zehrung, PATH, Seattle WA, USA.

We would also like to extend our thanks to Marion Gruber, United States Food and Drug Administration (US FDA), members of IPAC for their review and input, as well as the many individuals and institutions who provided comments on the draft at the public consultation stage.

## **Abbreviations**

	50% cell culture infectious dose
COGS	cost of goods sold
стс	controlled temperature chain
EMA	European Medicines Agency
gPPP	generic Preferred Product Profile
нсพ	health care worker
HF	human factors
ID	intradermal
IPAC	Immunization Practices Advisory Committee
IQR	inter-quartile range
LMIC	low- and middle-income countries
MAP	microarray patch
MCV1	measles-containing vaccine first dose
MCV2	measles-containing vaccine second dose
MMR	measles-mumps-rubella
MMRV	measles-mumps-rubella-varicella
MR	measles-rubella
NRA	national regulatory authority

NS

needle and syringe

ORI	outbreak response immunization
PDVAC	Product Development for Vaccines Advisory Committee
PQ	prequalified
PSPQ	Programmatic Suitability for Prequalification
РТТІ	peak temperature threshold indicator
RI	routine immunization
SAGE	Strategic Advisory Group of Experts on Immunization
SC	subcutaneous
SIAs	supplementary immunization activities
TCID <sub>50</sub>	50% tissue culture infective dose
ТРР	target product profile
UNICEF	United Nations Children's Fund
VPPAG	Vaccine Presentation and Packaging Advisory Group
VVM	vaccine vial monitor
VVM-TI	vaccine vial monitor with an integrated threshold indicator
<b>WHO</b>	World Health Organization

预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5\_25213